Single‐agent use of metformin, DDP‐4 inhibitors, alpha‐glucosidase inhibitors, GLP‐1RAs, and SGLT2 inhibitors is associated with a lower hypoglycemia risk.213. The gene discussed is SLC5A2; the disease is Hypoglycemia.